Selective binding of endostatin peptide 4 to recombinant VEGF receptor 3 in vitro

Protein and Peptide Letters

Volumn 22, Issue 11, 2015, Pages 1025-1030

  Han, Kyu Yeon ^a   Chang, Michael ^a   Ying, Hong Yu ^a   Lee, Hyun ^b   Huang, Yu Hui ^a   Chang, Jin Hong ^a   Azar, Dimitri T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Collagen XVIII; Endostatin; Neostatin; VEGFR1; VEGFR2 and VEGFR3

Indexed keywords

ENDOSTATIN; ENDOSTATIN PEPTIDE 4; ENDOSTATIN PEPTIDE 9; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN RECEPTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; COLLAGEN TYPE 18; PROTEIN BINDING; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; FAR WESTERN BLOTTING; IN VITRO STUDY; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE; CHEMISTRY; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; COLLAGEN TYPE XVIII; ENDOSTATINS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84947711591     PISSN: 09298665     EISSN: 18755305     Source Type: Journal    
DOI: 10.2174/0929866522666150907111953     Document Type: Article

References (19)

1. Kato, T.; Chang, J.H.; Azar, D.T. Expression of type XVIII collagen during healing of corneal incisions and keratectomy wounds. Invest. Ophthalmol. Visual Sci., 2003, 44, 78-85.
2. Fukai, N.; Eklund, L.; Marneros, A.G.; Oh, S.P.; Keene, D.R.; Tamarkin, L.; Niemela, M.; Ilves, M.; Li, E.; Pihlajaniemi, T.; Olsen, B.R. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J., 2002, 21, 1535-1544.
3. O'Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.S.; Flynn, E.; Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997, 88, 277-285.
4. Folkman, J. Angiogenesis and angiogenesis inhibition: An overview. Regulation of Angiogenesis, 1997, 79, 1-8.
5. Chang, J.H.; Gabison, E.E.; Kato, T.; Azar, D.T. Corneal neovascularization. Curr. Opin. Ophthalmol., 2001, 12, 242-249.
6. Ellenberg, D.; Azar, D.T.; Hallak, J.A.; Tobaigy, F.; Han, K.Y.; Jain, S.; Zhou, Z.; Chang, J.H. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog. Retin. Eye Res., 2010, 29, 208-248.
7. Azar, D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity. Trans. Am. Ophthalmol. Soc., 2006, 104, 264-302.
8. Chang, J.H.; Javier, J.A.; Chang, G.Y.; Oliveira, H.B.; Azar, D.T. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett., 2005, 579, 3601-3606.
9. Yeh, S.I.; Han, K.Y.; Sabri, A.; Rosenblatt, M.I.; Azar, D.T.; Jain, S.; Chang, J.H. MMP-7 knock-in corneal fibroblast cell lines secrete MMP-7 with proteolytic activity towards collagen XVIII. Curr. Eye Res., 2010, 35, 799-805.
10. Lin, H.C.; Chang, J.H.; Jain, S.; Gabison, E.E.; Kure, T.; Kato, T.; Fukai, N.; Azar, D.T. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest. Ophthalmol. Vis. Sci., 2001, 42, 2517-2524.
11. Kojima, T.; Azar, D.T.; Chang, J.H. Neostatin-7 regulates bFGFinduced corneal lymphangiogenesis. FEBS Lett., 2008, 582, 2515-2520.
12. Faye, C.; Moreau, C.; Chautard, E.; Jetne, R.; Fukai, N.; Ruggiero, F.; Humphries, M.J.; Olsen, B.R.; Ricard-Blum, S. Molecular interplay between endostatin, integrins, and heparan sulfate. J. Biolog. Chem., 2009, 284, 22029-22040.
13. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature and symbolism for amino acids and peptides. Recommendations, 1983. Biochem. J., 1984, 219, 345-373.
14. Han, K.Y.; Azar, D.T.; Sabri, A.; Lee, H.; Jain, S.; Lee, B.S.; Chang, J.H. Characterization of the interaction between endostatin short peptide and VEGF receptor. Protein Pept. Lett., 2012, 19, 969-974.
15. Hohenester, E.; Sasaki, T.; Olsen, B.R.; Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J., 1998, 17, 1656-1664.
16. Han, K.Y.; Chang, J.H.; Dugas-Ford, J.; Alexander, J.S.; Azar, D.T. Involvement of lysosomal degradation in VEGF-C-induced down-regulation of VEGFR-3. FEBS Lett., 2014, 588, 4357-4363.
17. Zhu, J.; Dugas-Ford, J.; Chang, M.; Purta, P.; Han, K.Y.; Hong, Y.K.; Dickinson, M.E.; Rosenblatt, M.I.; Chang, J.H.; Azar, D.T. Simultaneous in vivo imaging of blood and lymphatic vessel growth in Prox1-GFP/Flk1:myr-mCherry mice. FEBS J., 2015, 282, 1458-1467.
18. Chang, J.H.; Garg, N.K.; Lunde, E.; Han, K.Y.; Jain, S.; Azar, D.T. Corneal neovascularization: an anti-VEGF therapy review. Surv. Ophthalmol., 2012, 57, 415-429.
19. Karkkainen, M.J.; Ferrell, R.E.; Lawrence, E.C.; Kimak, M.A.; Levinson, K.L.; McTigue, M.A.; Alitalo, K.; Finegold, D.N. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet., 2000, 25, 153-159.